Cidofovir (Synonyms: GS-0504, (S)-HPMPC, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine) |
Catalog No.GC12666
One-Click Copy Product Info
|
Cidofovir dihydrate is an acyclic monophosphate nucleotide analog, a CMV inhibitor, possessing antiviral activity.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 113852-37-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cidofovir dihydrate is an acyclic monophosphate nucleotide analog, a CMV inhibitor, possessing antiviral activity[1-2]. Cidofovir dihydrate selectively inhibits viral DNA polymerase, thereby inhibiting cytomegalovirus replication and inducing apoptosis. Cidofovir dihydrate can be used in antiviral and cancer treatment-related research[3-4].
In vitro, MA104 cells were pretreated with Cidofovir dihydrate (50-400μM) for 6 hours, followed by infection with Human Bocavirus 1 (HBoV1) for 12 hours. Cidofovir dihydrate significantly inhibited HBoV1 replication, resulting in a dose-dependent reduction in viral DNA copy number[5]. HBoV1-HiBiTNS1-transfected HEK293T-LgBiT cells were treated with Cidofovir dihydrate (200μM) for 72 hours. Cidofovir dihydrate inhibited HBoV1 replicative activity[6].
In vivo, in an intracranial glioblastoma (GBM) xenograft mouse model, Cidofovir dihydrate (100mg/kg; intraperitoneal injection; 3 times per week) significantly extended the survival of tumor-bearing mice, induced apoptosis in tumor cells, and promoted DNA double-strand breaks while activating the p53 and Fas/TNFα-Trail pathways[7]. In a Monkeypox virus (MPXV) systemic dissemination SCID mouse model, early post-exposure administration of Cidofovir dihydrate (100mg/kg; subcutaneous injection; 2 times per week) on the day of infection or within 2 days post-infection significantly inhibited viral replication in organs such as the lungs, liver, and spleen, and alleviated histopathological damage[8].
References:
[1] Maggs DJ, Clarke HE. In vitro efficacy of ganciclovir, cidofovir, penciclovir, foscarnet, idoxuridine, and acyclovir against feline herpesvirus type-1. Am J Vet Res. 2004 Apr;65(4):399-403.
[2] Bray M, Martinez M, Smee DF, et al. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J Infect Dis. 2000 Jan;181(1):10-9.
[3] Kendle JB, Fan-Havard P. Cidofovir in the treatment of cytomegaloviral disease. Ann Pharmacother. 1998 Nov;32(11):1181-92.
[4] Stafford A, Rimmer S, Gilchrist M, et al. Use of cidofovir in a patient with severe mpox and uncontrolled HIV infection. Lancet Infect Dis. 2023 Jun;23(6):e218-e226.
[5] Tang J, Chen S, Deng Y, et al. MA104 cell line is permissive for human bocavirus 1 infection. J Virol. 2025 Feb 25;99(2):e0153924.
[6] Tang J, Chen S, Zhong Y, et al. Development of a reporter HBoV1 strain for antiviral drug screening and life cycle studies. Virol Sin. 2025 Apr;40(2):275-283.
[7] Hadaczek P, Ozawa T, Soroceanu L, et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin Cancer Res. 2013 Dec 1;19(23):6473-83.
[8] Cao X, Shi N, Qiu X, et al. Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice. Nat Commun. 2025 Dec 18;17(1):843.
| Cell experiment [1]: | |
Cell lines | MA104 cells (monkey kidney epithelial cell line) |
Preparation Method | MA104 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. For antiviral evaluation, MA104 cells in 12-well plates were treated with Cidofovir dihydrate (400µM, 200µM, 100µM, 50µM) for 6 hours before infection and then incubated with Human Bocavirus 1 (HBoV1) for 12 hours. After infection, cells were washed and cultured in fresh medium with or without Cidofovir dihydrate for the indicated duration. |
Reaction Conditions | 50-400μM; 6h pretreatment. |
Applications | Cidofovir dihydrate treatment resulted in a dose-dependent reduction in intracellular HBoV1 DNA copies compared to the untreated control. |
| Animal experiment [2]: | |
Animal models | Athymic nu/nu mice (homozygous) |
Preparation Method | Female athymic mice (5-6 weeks old) received intracerebral injection of 300,000 U87MG or SF7796 glioblastoma (GBM) cells into the right striatum to establish intracranial xenograft tumors. Mice were treated intraperitoneally (i.p.) with Cidofovir dihydrate at 100mg/kg, 3 times per week. Bioluminescence imaging was used to monitor tumor growth. |
Dosage form | 100mg/kg; i.p.; 3 times/week. |
Applications | Cidofovir dihydrate treatment significantly delayed or prevented intracranial GBM tumor development, as evidenced by reduced bioluminescence signal, and significantly extended the survival of tumor-bearing mice compared to the vehicle-only control group. In tumors, Cidofovir dihydrate induced extensive apoptosis, and promoted DNA double-stranded breaks. |
References: | |
| Cas No. | 113852-37-2 | SDF | |
| Synonyms | GS-0504, (S)-HPMPC, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine | ||
| Chemical Name | [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid | ||
| Canonical SMILES | C1=CN(C(=O)N=C1N)CC(CO)OCP(=O)(O)O | ||
| Formula | C8H14N3O6P | M.Wt | 279.19 |
| Solubility | ≥ 13.95mg/mL in Water with gentle warming | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5818 mL | 17.909 mL | 35.8179 mL |
| 5 mM | 716.4 μL | 3.5818 mL | 7.1636 mL |
| 10 mM | 358.2 μL | 1.7909 mL | 3.5818 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 9 reference(s) in Google Scholar.)